Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.
NextGen sequencing
cell-free DNA
cerebrospinal fluid (CSF)
circulating tumor DNA
liquid biopsy
pediatric brain tumors
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
pubmed:
12
2
2022
medline:
5
10
2022
entrez:
11
2
2022
Statut:
ppublish
Résumé
Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive diagnostic tests. We report our clinical experience with minimally invasive molecular diagnostics using a clinically validated assay for sequencing of cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part of clinical care, and results reported to both clinicians and patients/families. We analyzed 64 CSF samples from 45 pediatric, adolescent and young adult (AYA) patients (pediatric = 25; AYA = 20) with primary and recurrent brain tumors across 12 histopathological subtypes including high-grade glioma (n = 10), medulloblastoma (n = 10), pineoblastoma (n = 5), low-grade glioma (n = 4), diffuse leptomeningeal glioneuronal tumor (DLGNT) (n = 4), retinoblastoma (n = 4), ependymoma (n = 3), and other (n = 5). Somatic alterations were detected in 30/64 samples (46.9%) and in at least one sample per unique patient in 21/45 patients (46.6%). CSF cfDNA positivity was strongly associated with the presence of disseminated disease at the time of collection (81.5% of samples from patients with disseminated disease were positive). No association was seen between CSF cfDNA positivity and the timing of CSF collection during the patient's disease course. We identified three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making: (1) diagnosis and/or identification of actionable alterations; (2) monitor response to therapy; and (3) tracking tumor evolution. Our findings support broader implementation of clinical CSF cfDNA testing in this population to improve care.
Sections du résumé
BACKGROUND
Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive diagnostic tests.
METHODS
We report our clinical experience with minimally invasive molecular diagnostics using a clinically validated assay for sequencing of cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part of clinical care, and results reported to both clinicians and patients/families.
RESULTS
We analyzed 64 CSF samples from 45 pediatric, adolescent and young adult (AYA) patients (pediatric = 25; AYA = 20) with primary and recurrent brain tumors across 12 histopathological subtypes including high-grade glioma (n = 10), medulloblastoma (n = 10), pineoblastoma (n = 5), low-grade glioma (n = 4), diffuse leptomeningeal glioneuronal tumor (DLGNT) (n = 4), retinoblastoma (n = 4), ependymoma (n = 3), and other (n = 5). Somatic alterations were detected in 30/64 samples (46.9%) and in at least one sample per unique patient in 21/45 patients (46.6%). CSF cfDNA positivity was strongly associated with the presence of disseminated disease at the time of collection (81.5% of samples from patients with disseminated disease were positive). No association was seen between CSF cfDNA positivity and the timing of CSF collection during the patient's disease course.
CONCLUSIONS
We identified three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making: (1) diagnosis and/or identification of actionable alterations; (2) monitor response to therapy; and (3) tracking tumor evolution. Our findings support broader implementation of clinical CSF cfDNA testing in this population to improve care.
Identifiants
pubmed: 35148412
pii: 6527231
doi: 10.1093/neuonc/noac035
pmc: PMC9527510
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1763-1772Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Front Cell Dev Biol. 2020 Feb 18;8:45
pubmed: 32133357
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Nature. 2012 Feb 15;482(7386):529-33
pubmed: 22343890
Brain Tumor Pathol. 2018 Apr;35(2):97-105
pubmed: 29460200
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859
pubmed: 30322880
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Clin Chem. 2012 Mar;58(3):549-58
pubmed: 22052939
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
Nat Commun. 2020 Oct 27;11(1):5376
pubmed: 33110059
Neuro Oncol. 2017 May 1;19(5):699-709
pubmed: 28453743
Acta Neuropathol Commun. 2017 Apr 17;5(1):28
pubmed: 28416018
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
J Mol Diagn. 2021 Jun;23(6):742-752
pubmed: 33781965
Cancer Cell. 2021 Nov 8;39(11):1519-1530.e4
pubmed: 34678152
Mol Oncol. 2015 Nov;9(9):1737-43
pubmed: 26071350
Cancer Biol Ther. 2019;20(8):1057-1067
pubmed: 30990132
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Nat Genet. 2017 May;49(5):780-788
pubmed: 28394352
Cureus. 2019 Dec 3;11(12):e6281
pubmed: 31827999
Nat Rev Cancer. 2018 Apr;18(4):255-263
pubmed: 29376520
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821